Sorry!! The article you are trying to read is not available now.
Dynavax Technologies' Stock Plunges on Vaccine Safety Concern
MINYANVILLE ORIGINAL Dynavax Technologies' (NASDAQ:DVAX) stock is plummeting Friday after a panel of government advisers said it wasn’t convinced that the company’s experimental vaccine for hepatitis B was safe.   The advisers to the Food and Drug Administration voted 8-5 saying there wasn’t enough study data from the company to show Heplisav was safe. The advisers also voted 13-1 to support the apparent effectiveness of the vaccine in treating adults. The FDA will consider the panel recommendations and will make a decision on a possible approval by February 24. It’s not likely that the FDA is going to approve ...
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here